Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
14.10.2020 15:00:00 EEST | Business Wire | Press release
Boehringer Ingelheim and Oxford BioTherapeutics Ltd. (OBT) today announced they are building on their successful partnership and are establishing a new alliance to discover additional selective targets for strategic cancer indications to deliver first-in-class treatments for cancer patients. Boehringer Ingelheim will use OBT’s OGAP® platform to identify novel target opportunities for new immunotherapies utilizing their T-cell engager, cancer vaccine and oncolytic virus platforms. This follows the initiation of the first patient dosing in a Phase 1 clinical trial of a bispecific antibody for the treatment of patients with small cell lung carcinoma and other neoplasms, where the target for the bispecific antibody was discovered during the first phase of the partnership.
“This collaboration with Oxford BioTherapeutics is important for advancing therapeutic modalities that depend upon the identification of unique and specific tumor antigens within our cancer immunology portfolio,” said Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head Cancer Immunology & Immune Modulation Research at Boehringer Ingelheim. “We are committed to developing innovative, efficacious and safe treatment options for patients suffering from cancer, and these novel cancer target discoveries are a key step in the development of new potential treatments.”
“We view the hopeful discovery of additional tumor targets as further confirmation of the value of our OGAP® platform to identify novel targets that can be substrates for innovative new therapies,” said Christian Rohlff, Ph.D., Chief Executive Officer of OBT. “OBT’s platforms are designed to discover and validate novel therapeutic targets and we look forward to continuing our partnership with Boehringer Ingelheim to best address difficult-to-treat cancers.”
In addition to the programs in the partnership with Boehringer Ingelheim, OBT’s clinical assets have also been enabled through the OGAP® discovery platform. Selecting the right target is fundamental for the successful development of a truly first-in-class oncology product. OBT’s platforms are designed to discover novel therapeutic targets and engineer antibodies to those targets, including CAR-T, other T-cell and NK cell-mediated cytotoxicity (ADCC) therapeutics to best address difficult-to-treat cancers. A major differentiator between OBTs discovery platform and other approaches is the retention of the link between individual patient samples through to the design of therapeutic antibodies and diagnostic patient selection tools, increasing the overall successful transition into clinical development.
Financial terms of the expanded agreement are not being disclosed. Under the terms of the agreement, Boehringer Ingelheim is responsible for the development and commercialization of antibody product candidates that interact with the novel targets identified by OGAP®. OBT will receive development and regulatory milestone payments and royalties on any future product sales. To date, Boehringer Ingelheim has exercised two options under the first agreement and has selected two therapeutic candidates for further development.
Boehringer Ingelheim Oncology is taking cancer on by leading the science with cancer cell directed agents, immuno-oncology therapies and their combinations to address unmet needs in lung and gastrointestinal cancers. The company invests significantly in early stage research to identify unexplored and undrugged pathways of cancer. Learn more about Boehringer Ingelheim’s innovation in oncology here.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/collaboration-oxfordbiotherapeutics
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005517/en/
Contact information
Media Contacts:
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com
Linda Ruckel
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
linda.ruckel@boehringer-ingelheim.com
Contacts for OBT
Investors:
Lee Roth
212-213-0006, ext. 331
lroth@burnsmc.com
Media:
Ryo Imai / Robert Flamm, Ph.D.
212-213-0006, ext. 315 / 364
rimai@burnsmc.com / rflamm@burnsmc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 17:49:00 EET | Press release
INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globally. Now, INRIX is launching a new generation of automation and intelligence to help agencies and enterprises move faster from analyzing data to making deci
Check Point and ControlPlane Partner to Help Enterprises Securely Scale AI and Accelerate Agentic Innovation24.2.2026 16:30:00 EET | Press release
ControlPlane, a specialist AI Security and DevSecOps consultancy, and Check Point Software Technologies Ltd., a pioneer and global leader in cyber security solutions, today announced a strategic collaboration to help enterprises securely adopt Large Language Models (LLMs) and agentic AI systems at scale. The partnership delivers a comprehensive, regulator-ready security framework designed to reduce risk, protect sensitive data, and enable organizations to move confidently from AI experimentation to production deployment. By combining Check Point’s AI-native threat prevention platform with ControlPlane’s deep expertise in cloud native architectures and DevSecOps, enterprises can operationalize AI securely without slowing innovation. As organizations advance AI initiatives beyond pilots, they face a growing “AI readiness gap.” Emerging threats such as prompt injection, unauthorized access, data leakage, and model misuse introduce risks that traditional security controls were not built to
Andersen Consulting Expands Capabilities with Assure Consulting24.2.2026 16:30:00 EET | Press release
Andersen Consulting strengthens its platform with addition of collaborating firm Assure Consulting, a Germany-based management consulting firm specializing in project management and project portfolio management. Founded in 2003, Assure Consulting supports organizations in successfully delivering complex projects and transformations. The firm helps clients establish and operate Project Management Offices (PMOs), strengthen governance and portfolio management, and apply classical, agile, or hybrid project management approaches tailored to their needs. Assure Consulting also provides hands-on support for large-scale system and process rollouts, integrated change management for organizational and cultural transformation, and coaching and training programs aligned with internationally recognized project management standards to build sustainable capabilities within client organizations. “This collaboration allows us to scale our project-delivery expertise and agile transformation capabilitie
Clinilabs Establishes EU Headquarters in Basel, Strengthening European Clinical Operations Under New Regional Leadership24.2.2026 16:00:00 EET | Press release
Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced the expansion of its European operations, including the establishment of its European Union headquarters at Switzerland Innovation Park Basel Area, and the appointment of Dr. Anne-Marie Nagy as executive vice president and head of Clinilabs Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224669284/en/ Dr. Anne-Marie Nagy appointed as Executive Vice President and Head of Clinilabs Europe Switzerland Innovation Park Basel Area is part of Switzerland’s national innovation network and located within the Basel region’s globally recognized life sciences cluster, bringing together biopharma companies, research institutions, and clinical innovation leaders. “Europe is a critical pillar of Clinilabs’ long-term growth strategy,” said Gary K. Zammit, Ph.D., president and chie
Aeris and Verizon Business Simplify Global IoT Expansion with Unified Connectivity and Orchestration24.2.2026 16:00:00 EET | Press release
Aeris, a global leader in wireless management platforms, security services and connected vehicle programs, today announced an inbound IoT connectivity management relationship with Verizon Business to transform how multinational enterprises manage and scale international IoT deployments. The collaboration introduces Aeris IoTA Inbound Services, a solution that integrates the IoTA Connectivity Management Platform directly with Verizon ThingSpace platform to simplify multi-region operations. The collaboration has already enabled U.S.-based enterprises with outbound connectivity for international IoT deployments using Aeris IoTA, and this extension will broaden those capabilities by opening up the U.S. market for global device fleets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224143173/en/ Mark Cratsenburg - Chief Commercial Officer, IoT Business Unit, Aeris This innovative collaboration directly addresses the primary ch
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom